retatrutide phase 2 trial obesity triple agonist Another Promising Medication (Retatrutide) for Retatrutide Explained: The Triple Agonist

doi: 10.1177/03000605211060675, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 72

The GLP-1 medications mimic the action of GLP-1 release, resulting in a decreased appetite and feeling full after eating smaller amounts of food

With telogen effluvium, a stressor like rapid weight loss pushes a larger-than-normal percentage of hair follicles from the growth phase into the resting phase prematurely

It typically has fewer gastrointestinal side effects than Semaglutide GLP-1 and a lower risk of pancreatitis

Description Introducing Reta 15mg from SSP Research, a next-generation investigational compound studied for its impact on body weight regulation, glucose metabolism, and lipid balance